<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Chava S</submitter><funding>HHS | National Institutes of Health (NIH)</funding><funding>NCI NIH HHS</funding><funding>DOD | Department of Defense Education Activity (DoDEA)</funding><pagination>232-274</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12808752</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>18(1)</volume><pubmed_abstract>Natural Killer (NK) cells play a critical role in regulating tumor growth, but our understanding of the mechanisms underlying their anti-tumor activity remains limited. We identified the histone methyltransferase EHMT2 as a key suppressor of NK cell-mediated cytotoxicity. EHMT2 inhibition in cancer cells enhanced NK cell-mediated elimination of diverse cancers, including uveal melanoma, breast cancer, and pancreatic cancer. EHMT2 loss increased AZGP1 and decreased TGF-β1 levels, resulting in the autocrine elevation of NKG2D ligands MICB and ULBP3, chemokines in cancer cells, and the paracrine stimulation of NK cell function. In a syngeneic pancreatic cancer model, EHMT2 inhibition suppressed tumors in an NK cell-dependent manner, as NK cell depletion restored tumor growth. This effect pers</pubmed_abstract><journal>EMBO molecular medicine</journal><pubmed_title>Loss of EHMT2 enhances NK cell-driven anti-tumor immunity through TGF-β1 suppression.</pubmed_title><pmcid>PMC12808752</pmcid><funding_grant_id>F31 CA271673</funding_grant_id><funding_grant_id>R00CA241110</funding_grant_id><funding_grant_id>R01CA271673</funding_grant_id><funding_grant_id>R00 CA241110</funding_grant_id><funding_grant_id>HT9425-24-1-0593</funding_grant_id><pubmed_authors>Gupta R</pubmed_authors><pubmed_authors>Wajapeyee N</pubmed_authors><pubmed_authors>Ma B</pubmed_authors><pubmed_authors>Malvi P</pubmed_authors><pubmed_authors>DeMarco KD</pubmed_authors><pubmed_authors>Bugide S</pubmed_authors><pubmed_authors>Ruscetti M</pubmed_authors><pubmed_authors>Zajac A</pubmed_authors><pubmed_authors>Chava S</pubmed_authors><pubmed_authors>Parikh CN</pubmed_authors><pubmed_authors>Cai G</pubmed_authors></additional><is_claimable>false</is_claimable><name>Loss of EHMT2 enhances NK cell-driven anti-tumor immunity through TGF-β1 suppression.</name><description>Natural Killer (NK) cells play a critical role in regulating tumor growth, but our understanding of the mechanisms underlying their anti-tumor activity remains limited. We identified the histone methyltransferase EHMT2 as a key suppressor of NK cell-mediated cytotoxicity. EHMT2 inhibition in cancer cells enhanced NK cell-mediated elimination of diverse cancers, including uveal melanoma, breast cancer, and pancreatic cancer. EHMT2 loss increased AZGP1 and decreased TGF-β1 levels, resulting in the autocrine elevation of NKG2D ligands MICB and ULBP3, chemokines in cancer cells, and the paracrine stimulation of NK cell function. In a syngeneic pancreatic cancer model, EHMT2 inhibition suppressed tumors in an NK cell-dependent manner, as NK cell depletion restored tumor growth. This effect pers</description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Jan</publication><modification>2026-06-12T04:52:21.325Z</modification><creation>2026-06-12T03:07:44.676Z</creation></dates><accession>S-EPMC12808752</accession><cross_references><pubmed>41366520</pubmed><doi>10.1038/s44321-025-00357-6</doi></cross_references></HashMap>